VCAM-1 targeted alpha-particle therapy for early brain metastases

BACKGROUND: Brain metastases (BM) develop frequently in patients with breast cancer. Despite the use of external beam radiotherapy (EBRT), the average overall survival is short (6 months from diagnosis). The therapeutic challenge is to deliver molecularly targeted therapy at an early stage when rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Corroyer-Dulmont, Aurélien, Valable, Samuel, Falzone, Nadia, Frelin-Labalme, Anne-Marie, Tietz, Ole, Toutain, Jérôme, Soto, Manuel Sarmiento, Divoux, Didier, Chazalviel, Laurent, Pérès, Elodie A, Sibson, Nicola R, Vallis, Katherine A, Bernaudin, Myriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162423/
https://www.ncbi.nlm.nih.gov/pubmed/31538194
http://dx.doi.org/10.1093/neuonc/noz169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162423/
https://www.ncbi.nlm.nih.gov/pubmed/31538194
http://dx.doi.org/10.1093/neuonc/noz169

Ejemplares similares